RTS,S trial sites

African researchers at forefront of partnership

A product development partnership involving the PATH Malaria Vaccine Initiative (MVI) and GlaxoSmithKline Vaccines—and with top African researchers at the forefront—is conducting the Phase 3 efficacy trial of RTS,S.

Click on the sites in the map below to learn more about our partners in Africa.

Map of RTS,S sites. Nanoro, Burkina Faso Kintampo, Ghana Kumasi/Agogo, Ghana Lambarene, Gabon Manhica, Mozambique Lilongwe, Malawi Bagamoyo, Tanzania Korogwe, Tanzania Kilifi, Kenya Siaya, Kenya Kombewa, Kenya

Trial sites

The RTS,S Phase 3 efficacy trial is ongoing in seven African countries.

Nanoro, Burkina Faso
Principal Investigator: Tinto Halidou
Co-Principal Investigator: Umberto D'Alessandro
Children enrolled: 1,281
Partner: Institut de Recherche en Science de la Sante/Centre Muraz (IRSS-DRO)

Read the spotlight: Dr. Tinto Halidou, malaria vaccine researcher and advocate.

Lambaréné, Gabon
Principal Investigator: Selidji Agnandji (Maxime)
Co-Principal Investigator: Bertrand Lell
Children enrolled: 930
Partner: Albert Schweitzer Hospital (HAS)

Kumasi/Agogo, Ghana
Principal Investigator: Daniel Ansong
Co-Principal Investigator: Tsiri Agbenyega
Children enrolled: 1,288
Partner: Kwame Nkrumah University of Science and Technology (KNUST)

Read the feature: Ghanaian scientist mixes malaria vaccine research with grassroots practicality.

Back to top

Kintampo, Ghana
Principal Investigator: Seth Owusu-Agyei
Co-Principal Investigator: Kwaku Poku Asante
Children enrolled: 1,334
Partner: Kintampo Health Research Center (KHRC)

Total study population (15,460)
Children 5 months to 17 months old (8,923)
Children 6 weeks to 12 weeks old (6,537)
Enrollment period: May 26, 2009 to January 31, 2011

Kilifi, Kenya
Principal Investigator: Patricia Njuguna
Co-Principal Investigator: Kevin Marsh
Children enrolled: 904
Partner: KEMRI Wellcome Collaborative Research Programme

Read the feature: African malaria vaccine researcher discusses late-stage clinical trial.

Read the feature: How to decide when to take a malaria vaccine to Africa.

Kombewa, Kenya
Principal Investigator: Walter Otieno
Co-Principal Investigator: Lucas Otieno
Children enrolled: 1,631
Partner: KEMRI/Walter Reed Army Institute of Research

Back to top

Siaya, Kenya
Principal Investigator: Mary Hamel
Co-Principal Investigator: Simon Kariuki
Children enrolled: 1,620
Partner: KEMRI/Centers for Disease Control and Prevention

Read the feature: Kenya's Siaya District Hospital improves health care thanks to malaria vaccine studies.

Lilongwe, Malawi
Principal Investigator: Francis Martinson
Co-Principal Investigator: Irving Hoffman
Children enrolled: 1,626
Partner: University of North Carolina (UNC) Project

Read the feature: Malawi villagers caught in cycle of debilitating routines.

Manhiça, Mozambique
Principal Investigator: Pedro Alonso
Co-Principal Investigator: Pedro Aide
Children enrolled: 1,637
Partner: Centro de InvestigaƧao em Saude de ManhiƧa (CISM)

Back to top

Bagamoyo, Tanzania
Principal Investigator: Salim Abdulla
Co-Principal Investigator: Marcel Tanner
Children enrolled: 1,705
Partner: Ifakara Health Institute (IHI)

Read the feature: World's most clinically advanced malaria vaccine candidate enters Phase 3 testing.

Read the feature: Full enrollment achieved in large-scale Phase 3 malaria vaccine candidate trial.

Korogwe, Tanzania
Principal Investigator: John Lusingu
Co-Principal Investigator: Samwel Gesase
Children enrolled: 1,505
Partner: Joint Malaria Programme (JMP), National Institute of Medical Research (NIMR)

Read the feature: Working to develop a malaria vaccine.

Back to top